Search

Your search keyword '"Grasso, Roberta"' showing total 37 results
Start Over Author "Grasso, Roberta"
37 results on '"Grasso, Roberta"'

1. Video Calls During the COVID-19 Pandemic: A Bridge for Patients, Families, and Respiratory Therapists

Author

Maffoni, Marina, Torlaschi, Valeria, Pierobon, Antonia, Zanatta, Francesco, Grasso, Roberta, Bagliani, Stefania, Govoni, Luca, Biglieri, Milena, Cerri, Luca, Geraci, Luca, Salvaneschi, Giulia, and Piaggi, Giancarlo

Subjects
Epidemics -- Influence -- Italy, Patients -- Care and treatment, Telemedicine -- Forecasts and trends -- Usage, Market trend/market analysis, Family and marriage, Health, Psychology and mental health
Abstract

Background: In response to COVID-19 pandemic outbreak, healthcare procedures and modalities have changed considerably. Video calls may supply valid support for health care professionals, contributing to maintaining the communication between hospitalized patients and their families. The present study aimed to observe the experience of a group of respiratory therapists who conducted video calls between patients and their families in a COVID-19 unit. Method: Semistructured interviews (20-30 minutes duration) with the respiratory therapists who conducted the video calls in a COVID-19 unit in the North of Italy were performed. Participants joined the study voluntarily and, after receiving the informed consent, the interviews were audio-recorded. To better understand healthcare professionals' experience, the Interpretive Description methodology was adopted. Results: Seven respiratory therapists (three males, four females; mean age 45.1 [+ or -] 14.4) were recruited. Sixteen codes emerged from the analysis, constituting five primary themes: Contact, Impact, Challenges, Centering, and Future. Conclusions: The findings shed light on the usability of video calls during this emergency period and their potential for future implementation. Specifically, this type of call may bridge the distances in such periods of care and help professionals to emotionally support patients and caregivers. Public Significance Statement Overall, these findings provide first suggestions to the healthcare system concerning both professionals' and patients/caregivers' needs in dealing with new technologies. Keywords: COVID-19, healthcare professionals, qualitative research, respiratory therapists, video call, Within health care settings, care pathways have changed considerably since the COVID-19 pandemic outbreak (Greenhalgh, Koh, & Car, 2020; Greenhalgh, Wherton, et al., 2020; Rose, 2020; Thornton, 2020). Hospitals became [...]

Published
2021

4. Cladribine vs other drugs in MS: Merging randomized trial with real-life data

Author

Signori, Alessio, Saccà, Francesco, Lanzillo, Roberta, Maniscalco, Giorgia Teresa, Signoriello, Elisabetta, Repice, Anna Maria, Annovazzi, Pietro, Baroncini, Damiano, Clerico, Marinella, Binello, Eleonora, Cerqua, Raffaella, Mataluni, Giorgia, Perini, Paola, Bonavita, Simona, Lavorgna, Luigi, Zarbo, Ignazio Roberto, Laroni, Alice, Pareja-Gutierrez, Lorena, La Gioia, Sara, Frigeni, Barbara, Barcella, Valeria, Frau, Jessica, Cocco, Eleonora, Fenu, Giuseppe, Clerici, Valentina Torri, Sartori, Arianna, Rasia, Sarah, Cordioli, Cinzia, Stromillo, Maria Laura, Di Sapio, Alessia, Pontecorvo, Simona, Grasso, Roberta, Barone, Stefania, Barrilà, Caterina, Russo, Cinzia Valeria, Esposito, Sabrina, Ippolito, Domenico, Landi, Doriana, Visconti, Andrea, and Sormani, Maria Pia

Published
2020
Full Text
View/download PDF

8. A real‐world study of alemtuzumab in a cohort of Italian patients

Author

Russo, Cinzia Valeria, primary, Saccà, Francesco, additional, Frau, Jessica, additional, Annovazzi, Pietro, additional, Signoriello, Elisabetta, additional, Bonavita, Simona, additional, Grasso, Roberta, additional, Clerico, Marinella, additional, Cordioli, Cinzia, additional, Laroni, Alice, additional, Capobianco, Marco, additional, Torri Clerici, Valentina, additional, Sartori, Arianna, additional, Cavalla, Paola, additional, Maniscalco, Giorgia Teresa, additional, La Gioia, Sara, additional, Caleri, Francesca, additional, Giugno, Alessia, additional, Iodice, Rosa, additional, Carotenuto, Antonio, additional, Cocco, Eleonora, additional, Fenu, Giuseppe, additional, Zaffaroni, Mauro, additional, Baroncini, Damiano, additional, Lus, Giacomo, additional, Gallo, Antonio, additional, De Mercanti, Stefania Federica, additional, Lapucci, Caterina, additional, Di Francescantonio, Valeria, additional, Brambilla, Laura, additional, Sormani, Maria Pia, additional, and Signori, Alessio, additional

Published
2021
Full Text
View/download PDF

10. First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study

Author

Maniscalco, Giorgia T., primary, Saccà, Francesco, additional, Lanzillo, Roberta, additional, Annovazzi, Pietro, additional, Baroncini, Damiano, additional, Binello, Eleonora, additional, Repice, Annamaria, additional, Perini, Paola, additional, Clerico, Marinella, additional, Mataluni, Giorgia, additional, Bonavita, Simona, additional, La Gioia, Sara, additional, Gutierrez, Lorena Pareja, additional, Laroni, Alice, additional, Frau, Jessica, additional, Cocco, Eleonora, additional, Torri Clerici, Valentina, additional, Zarbo, Ignazio Roberto, additional, Sartori, Arianna, additional, Signoriello, Elisabetta, additional, Rasia, Sarah, additional, Cordioli, Cinzia, additional, Stromillo, Maria Laura, additional, Cerqua, Raffaella, additional, Pontecorvo, Simona, additional, Di Sapio, Alessia, additional, Grasso, Roberta, additional, Barone, Stefania, additional, Lavorgna, Luigi, additional, Barrilà, Caterina, additional, Landi, Doriana, additional, Russo, Cinzia Valeria, additional, Frigeni, Barbara, additional, Ippolito, Domenico, additional, Turano, Gabriella, additional, Carmisciano, Luca, additional, Sormani, Maria Pia, additional, and Signori, Alessio, additional

Published
2020
Full Text
View/download PDF

11. A real‐world study of alemtuzumab in a cohort of Italian patients.

Author

Russo, Cinzia Valeria, Saccà, Francesco, Frau, Jessica, Annovazzi, Pietro, Signoriello, Elisabetta, Bonavita, Simona, Grasso, Roberta, Clerico, Marinella, Cordioli, Cinzia, Laroni, Alice, Capobianco, Marco, Torri Clerici, Valentina, Sartori, Arianna, Cavalla, Paola, Maniscalco, Giorgia Teresa, La Gioia, Sara, Caleri, Francesca, Giugno, Alessia, Iodice, Rosa, and Carotenuto, Antonio

Subjects
MAGNETIC resonance imaging, GLATIRAMER acetate, NATALIZUMAB, ALEMTUZUMAB, PROGRESSION-free survival
Abstract

Background and purpose: Real‐world data on alemtuzumab are limited and do not provide evidence of its effectiveness after various disease‐modifying therapies (DMTs). Our aim was to provide real‐world data on the impact of clinical variables and previous DMTs on clinical response to alemtuzumab. Methods: Sixteen Italian multiple sclerosis centers retrospectively included patients who started alemtuzumab from January 2015 to December 2018, and recorded demographics, previous therapies, washout duration, relapses, Expanded Disability Status Scale (EDSS) score, and magnetic resonance imaging data. Negative binomial regression models were used to assess the effect of factors on annualized relapse (ARR) after alemtuzumab initiation. Results: We studied 322 patients (mean age 36.8 years, median EDSS score 3, median follow‐up 1.94 years). Previous treatments were: fingolimod (106), natalizumab (80), first‐line oral agents (56), first‐line injectables (interferon/glatiramer acetate; 30), and other drugs (15). Thirty‐five patients were treatment‐naïve. The pre‐alemtuzumab ARR was 0.99 and decreased to 0.13 during alemtuzumab treatment (p < 0.001). The number of previous‐year relapses was associated with alemtuzumab ARR (adjusted risk ratio [RR] 1.38, p = 0.009). Progression‐free survival was 94.5% after 1 year, and 89.2% after 2 years of alemtuzumab treatment. EDSS score improvement occurred in 13.5% after 1 year, and 20.6% after 2 years. Re‐baselining patients after 6 months of alemtuzumab treatment, led to no evidence of disease activity status in 71.6% after 1 year and 58.9% after 2 years. Conclusions: Alemtuzumab decreases ARR independent of previous therapy, including patients with disease activity during natalizumab treatment. Overall, 90% of patients showed no disease progression, and 20% an improvement after 2 years of alemtuzumab. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

12. MSJ790390_supplementary_material – Supplemental material for Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study

Author

Saccà, Francesco, Lanzillo, Roberta, Signori, Alessio, Maniscalco, Giorgia T, Signoriello, Elisabetta, Fermo, Salvatore Lo, Repice, Annamaria, Annovazzi, Pietro, Baroncini, Damiano, Clerico, Marinella, Binello, Eleonora, Cerqua, Raffaella, Mataluni, Giorgia, Bonavita, Simona, Lavorgna, Luigi, Zarbo, Ignazio Roberto, Laroni, Alice, Rossi, Silvia, Gutierrez, Lorena Pareja, Gioia, Sara La, Frigeni, Barbara, Barcella, Valeria, Frau, Jessica, Cocco, Eleonora, Fenu, Giuseppe, Clerici, Valentina Torri, Sartori, Arianna, Rasia, Sarah, Cordioli, Cinzia, Sapio, Alessia Di, Pontecorvo, Simona, Grasso, Roberta, Barrilà, Caterina, Russo, Cinzia Valeria, Esposito, Sabrina, Ippolito, Domenico, Bovis, Francesca, Gallo, Fabio, and Sormani, Maria Pia

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, MSJ790390_supplementary_material for Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study by Francesco Saccà, Roberta Lanzillo, Alessio Signori, Giorgia T Maniscalco, Elisabetta Signoriello, Salvatore Lo Fermo, Annamaria Repice, Pietro Annovazzi, Damiano Baroncini, Marinella Clerico, Eleonora Binello, Raffaella Cerqua, Giorgia Mataluni, Simona Bonavita, Luigi Lavorgna, Ignazio Roberto Zarbo, Alice Laroni, Silvia Rossi, Lorena Pareja Gutierrez, Sara La Gioia, Barbara Frigeni, Valeria Barcella, Jessica Frau, Eleonora Cocco, Giuseppe Fenu, Valentina Torri Clerici, Arianna Sartori, Sarah Rasia, Cinzia Cordioli, Alessia Di Sapio, Simona Pontecorvo, Roberta Grasso, Caterina Barrilà, Cinzia Valeria Russo, Sabrina Esposito, Domenico Ippolito, Francesca Bovis, Fabio Gallo and Maria Pia Sormani in Multiple Sclerosis Journal

Published
2018
Full Text
View/download PDF

13. Prognostic indicators in pediatric clinically isolated syndrome

Author

Iaffaldano, Pietro, Simone, Marta, Lucisano, Giuseppe, Ghezzi, Angelo, Coniglio, Gabriella, Brescia Morra, Vincenzo, Salemi, Giuseppe, Patti, Francesco, Lugaresi, Alessandra, Izquierdo, Guillermo, Bergamaschi, Roberto, Cabrera-Gomez, Jose Antonio, Pozzilli, Carlo, Millefiorini, Enrico, Alroughani, Raed, Boz, Cavit, Pucci, Eugenio, Zimatore, Giovanni Bosco, Sola, Patrizia, Lus, Giacomo, Maimone, Davide, Avolio, Carlo, Cocco, Eleonora, Sajedi, Seyed Aidin, Costantino, Gianfranco, Duquette, Pierre, Shaygannejad, Vahid, Petersen, Thor, Fernández Bolaños, Ricardo, Paolicelli, Damiano, Tortorella, Carla, Spelman, Tim, Margari, Lucia, Amato, Maria Pia, Comi, Giancarlo, Butzkueven, Helmut, Trojano, Maria, Spitaleri, Daniele, Rottoli, Maria Rosa, Ardito, Bonaventura, Iuliano, Gerardo, Montanari, Enrico, Granieri, Enrico, Tedeschi, Gioacchino, Bertolotto, Antonio, Granella, Franco, Di Battista, Giancarlo, Gallo, Paolo, Cavalla, Paola, Bellantonio, Paolo, De Robertis, Francesca, Durelli, Luca, Scarpini, Elio, Rezzonico, Monica, Protti, Alessandra, Solaro, Claudio, Corea, Francesco, Bosco, Antonio, Vianello, Marika, Ferrò, Maria Teresa, Balgera, Roberto, Grasso, Roberta, De Luca, Giovanna, Farina, Deboah, Travaglini, Daniela, di Ioia, Maria, Di Tommaso, Valeria, Mancinelli, Luca, Pietrolongo, Erika, Hupperts, Raymond, Rio, Maria Edite, Terzi, Murat, Barnett, Michael, Slee, Mark, Van Pesch, Vincent, Savino, Aldo, Lechner-Scott, Jeannette, Grammond, Pierre, Singhal, Bhim, Zwanikken, Cees, Fiol, Marcela, Patrucco, Liliana, Paine, Mark, Mccombefrom, Pamela, Grand'Maison, Francois, Iaffaldano, Pietro, Simone, Marta, Lucisano, Giuseppe, Ghezzi, Angelo, Coniglio, Gabriella, Brescia Morra, Vincenzo, Salemi, Giuseppe, Patti, Francesco, Lugaresi, Alessandra, Izquierdo, Guillermo, Bergamaschi, Roberto, Cabrera-Gomez, Jose Antonio, Pozzilli, Carlo, Millefiorini, Enrico, Alroughani, Raed, Boz, Cavit, Pucci, Eugenio, Zimatore, Giovanni Bosco, Sola, Patrizia, Lus, Giacomo, Maimone, Davide, Avolio, Carlo, Cocco, Eleonora, Sajedi, Seyed Aidin, Costantino, Gianfranco, Duquette, Pierre, Shaygannejad, Vahid, Petersen, Thor, Fernández Bolaños, Ricardo, Paolicelli, Damiano, Tortorella, Carla, Spelman, Tim, Margari, Lucia, Amato, Maria Pia, Comi, Giancarlo, Butzkueven, Helmut, Trojano, Maria, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, MUMC+: MA Med Staf Spec Neurologie (9), Klinische Neurowetenschappen, Morra, Vincenzo Brescia, Cabrera Gomez, Jose Antonio, and Bolaños, Ricardo Fernández

Subjects
Registrie, Male, Multiple Sclerosis, Adolescent, Age of Onset, Child, Demyelinating Diseases, Female, Follow-Up Studies, Humans, Prognosis, Retrospective Studies, Risk Factors, Disease Progression, Registries, Neurology, Neurology (clinical), Prognosi, ONSET MULTIPLE-SCLEROSIS, CHILDHOOD, CHILDREN, PARACLINICAL FEATURES, DISABILITY PROGRESSION, NO, Follow-Up Studie, Retrospective Studie, prognostic indicators, Multiple Sclerosi, pediatric, multiple sclerosis, prognosis, indicators, OPTIC NEURITIS, Risk Factor, Demyelinating Disease, NATURAL-HISTORY, multiple sclerosis, clinically isolated syndrome, prognostic indicators, TRANSVERSE MYELITIS, clinically isolated syndrome, INTERFERON BETA-1B, Settore MED/26 - Neurologia, FOLLOW-UP, Human
Abstract

To assess prognostic factors for a second clinical attack and a first disability worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of Multiple Sclerosis (MS) patients. Objective: To assess prognostic factors for a second clinical attack and a first disability-worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of multiple sclerosis (MS) patients. Methods: A cohort of 770 pCIS patients was followed up for at least 10 years. Cox proportional hazard models and Recursive Partitioning and Amalgamation (RECPAM) tree-regression were used to analyze data. Results: In pCIS, female sex and a multifocal onset were risk factors for a second clinical attack (hazard ratio [HR], 95% confidence interval [CI] = 1.28, 1.06–1.55; 1.42, 1.10–1.84, respectively), whereas disease-modifying drug (DMD) exposure reduced this risk (HR, 95% CI = 0.75, 0.60–0.95). After pediatric onset MS (POMS) diagnosis, age at onset younger than 15 years and DMD exposure decreased the risk of a first Expanded Disability Status Scale (EDSS)-worsening event (HR, 95% CI = 0.59, 0.42–0.83; 0.75, 0.71–0.80, respectively), whereas the occurrence of relapse increased this risk (HR, 95% CI = 5.08, 3.46–7.46). An exploratory RECPAM analysis highlighted a significantly higher incidence of a first EDSS-worsening event in patients with multifocal or isolated spinal cord or optic neuritis involvement at onset in comparison to those with an isolated supratentorial or brainstem syndrome. A Cox regression model including RECPAM classes confirmed DMD exposure as the most protective factor against EDSS-worsening events and relapses as the most important risk factor for attaining EDSS worsening. Interpretation: This work represents a step forward in identifying predictors of unfavorable course in pCIS and POMS and supports a protective effect of early DMD treatment in preventing MS development and disability accumulation in this population. Ann Neurol 2017;81:729–739.

Published
2017

15. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study

Author

Saccà, Francesco, primary, Lanzillo, Roberta, additional, Signori, Alessio, additional, Maniscalco, Giorgia T, additional, Signoriello, Elisabetta, additional, Lo Fermo, Salvatore, additional, Repice, Annamaria, additional, Annovazzi, Pietro, additional, Baroncini, Damiano, additional, Clerico, Marinella, additional, Binello, Eleonora, additional, Cerqua, Raffaella, additional, Mataluni, Giorgia, additional, Bonavita, Simona, additional, Lavorgna, Luigi, additional, Zarbo, Ignazio Roberto, additional, Laroni, Alice, additional, Rossi, Silvia, additional, Pareja Gutierrez, Lorena, additional, La Gioia, Sara, additional, Frigeni, Barbara, additional, Barcella, Valeria, additional, Frau, Jessica, additional, Cocco, Eleonora, additional, Fenu, Giuseppe, additional, Torri Clerici, Valentina, additional, Sartori, Arianna, additional, Rasia, Sarah, additional, Cordioli, Cinzia, additional, Di Sapio, Alessia, additional, Pontecorvo, Simona, additional, Grasso, Roberta, additional, Barrilà, Caterina, additional, Russo, Cinzia Valeria, additional, Esposito, Sabrina, additional, Ippolito, Domenico, additional, Bovis, Francesca, additional, Gallo, Fabio, additional, and Sormani, Maria Pia, additional

Published
2018
Full Text
View/download PDF

16. Full-Thickness Excision versus Shaving by Laparoscopy for Intestinal Deep Infiltrating Endometriosis: Rationale and Potential Treatment Options

Author

Laganà, Antonio Simone, Vitale, Salvatore Giovanni, Trovato, Maria Antonietta, Palmara, Vittorio Italo, Rapisarda, Agnese Maria Chiara, Granese, Roberta, Sturlese, Emanuele, De Dominici, Rosanna, Alecci, Stefano, Padula, Francesco, Chiofalo, Benito, Grasso, Roberta, Cignini, Pietro, D’Amico, Paolo, and Triolo, Onofrio

Subjects
Article Subject
Abstract

Endometriosis is defined as the presence of endometrial mucosa (glands and stroma) abnormally implanted in locations other than the uterine cavity. Deep infiltrating endometriosis (DIE) is considered the most aggressive presentation of the disease, penetrating more than 5 mm in affected tissues, and it is reported in approximately 20% of all women with endometriosis. DIE can cause a complete distortion of the pelvic anatomy and it mainly involves uterosacral ligaments, bladder, rectovaginal septum, rectum, and rectosigmoid colon. This review describes the state of the art in laparoscopic approach for DIE with a special interest in intestinal involvement, according to recent literature findings. Our attention has been focused particularly on full-thickness excision versus shaving technique in deep endometriosis intestinal involvement. Particularly, the aim of this paper is clarifying from the clinical and methodological points of view the best surgical treatment of deep intestinal endometriosis, since there is no standard of care in the literature and in different surgical settings. Indeed, this review tries to suggest when it is advisable to manage the full-thickness excision or the shaving technique, also analyzing perioperative management, main complications, and surgical outcomes.

Published
2016
Full Text
View/download PDF

23. An unusual form of mirror syndrome: a case report

Author

Giacobbe, Annamaria, primary, Grasso, Roberta, additional, Interdonato, Maria Lieta, additional, Laganà, Antonio Simone, additional, Valentina, Giacobbe, additional, Triolo, Onofrio, additional, and Mancuso, Alfredo, additional

Published
2012
Full Text
View/download PDF

25. GETCOO TRAVEL : QUANDO L'INTELLIGENZA AR TIFICIALE INCONTRA L'ARTE.

Author

Grasso, Roberta

Abstract

GetCOO Travel is an innovative travel app for Android and iOS that, using image recognition, identifies monuments and artworks. GETCOO, that developed this app, is a very promising startup that works in the Computer Vision field. GETCOO developed a proprietary Artificial Intelligence technology named DART (Direct Acquisition and ReTrieval) that can identify not just generic categories but also specific objects. DART can be applied to identify basically anything, including monuments and artworks. GetCOO Travel works worldwide indoor and outdoor. With a single travel app, tourist can discover information about monuments and artworks simply by shooting them a photo. A smarter, lighter and more scalable solution with respect to dedicated apps, QR-codes and beacons. [ABSTRACT FROM AUTHOR]

Published
2018

27. The Persistence of p190 BCR-ABL Transcripts Is Associated with Lower Probability of Molecular Response to Imatinib in Early and Late Chronic Phase CML Patients.

Author

Garuti, Anna, primary, Ibatici, Adalberto, additional, Cirmena, Gabriella, additional, Miglino, Maurizio, additional, Varaldo, Riccardo, additional, Nicoletta, Colombo, additional, Grasso, Roberta, additional, Pozzi, Sarah, additional, Podesta, Marina, additional, Gobbi, Marco, additional, Sessarego, Mario, additional, Patrone, Franco, additional, and Frassoni, Francesco, additional

Published
2005
Full Text
View/download PDF

28. Sjögren's syndrome associated with antiphospholipid syndrome and fetal myocardial echogenicity: case report.

Author

Giacobbe, Annamaria, Grasso, Roberta, Foti, Grazia, Interdonato, Maria Lieta, and Mancuso, Alfredo

Subjects
*PREGNANCY, *ANTIPHOSPHOLIPID syndrome, *CONGENITAL heart disease, *ADRENOCORTICAL hormones, *ULTRASONIC imaging
Abstract

Introduction: Sjögren's syndrome is a rare systemic autoimmune disorder associated with pregnancy (0.3-0.6%). The typical occurrence of anti-Ro/SSA and anti-La/SSB autoantibodies in the maternal serum can modify the perinatal outcome: neonatal lupus and congenital heart block are the most common fetal complications. Case: we report a case of pregnancy complicated by a secondary form of SS associated with antiphospholipid syndrome and fetal myocardial echogenicity. Conclusion: in conclusion, increased attention must be paid to pregnancies associated with autoimmune disorders, since careful ultrasonographic and clinical monitoring and preventive treatment with corticosteroids could minimize severe and common fetal complications. [ABSTRACT FROM AUTHOR]

Published
2013

29. An unusual form of mirror syndrome: a case report.

Author

Giacobbe, Annamaria, Grasso, Roberta, Interdonato, Maria Lieta, Laganà, Antonio Simone, Valentina, Giacobbe, Triolo, Onofrio, and Mancuso, Alfredo

Subjects
*CASE studies, *EDEMA, *PREECLAMPSIA, *INFANT mortality, *PERINATAL death, MORTALITY risk factors
Abstract

Aim: Mirror syndrome is a triad consisting of fetal hydrops, maternal edema and placentomegaly. Its pathogenesis is unclear and it is frequently mistaken for preeclampsia, even though distinguishing features can be identified. It is associated with an increase in fetal mortality and maternal morbility. Methods: We report an uncommon case of mirror syndrome, which appeared late in pregnancy (38 weeks) in a young nulliparous and characterized by sudden and massive vulvar edema, with placentomegaly and hydramnios but without fetal hydrops. Results: Our report is an interesting example of an unusual form of Mirror syndrome for several reasons. First of all, the gestational age in which the disorder appeared differs remarkably from the data of literature; in our case, clinical signs and symptoms appeared only at 37 weeks. Another difference consists in the lack of hypertension that represents the second most common symptom associated and explains the difficulty to differentiate this syndrome from preeclampsia. Conclusions: Although mirror syndrome is associated with an increase in perinatal mortality, in the case we reported the late onset of the disorder associated with the medical treatment and the timely decision to perform a caesarean section allowed the birth of a healthy baby. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

30. The influence of planned kinds of delivery on pregnant women's emotional state.

Author

Giacobbe, Annamaria, Maggio Savasta, Laura, De Dominici, Rosanna, De Vivo, Antonio, Giacobbe, Valentina, Grasso, Roberta, Triolo, Onofrio, and Mancuso, Alfredo

Subjects
PREGNANCY & psychology, CESAREAN section, LABOR (Obstetrics), DEPRESSION in women, ANXIETY in women
Abstract

Objective: To evaluate if labour induction and elective caesarean section could influence anxiety and depression in pregnant women. Methods: One hundred and sixteen consecutive pregnant women with uncomplicated singleton pregnancy at term, scheduled for these two obstetric procedures were enrolled. An anonymous questionnaire with two self-rating instruments STAI and HAM-A for anxiety and HAM-D for depression was administered. Results: Anxiety levels did not show significant differences while a light depressive mood was evidenced among pregnant women waiting for labour induction ( p = 0.01). Conclusions: An adequate psychological support could be considered a helpful tool for pregnant women scheduled for labour induction. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

32. A real‐world study of alemtuzumab in a cohort of Italian patients

Author

Paola Cavalla, Laura Brambilla, Roberta Grasso, Cinzia Cordioli, Alice Laroni, Alessia Giugno, Valentina Torri Clerici, Maria Pia Sormani, Pietro Annovazzi, Francesco Saccà, Eleonora Cocco, Jessica Frau, Elisabetta Signoriello, Antonio Gallo, Marinella Clerico, Stefania Federica De Mercanti, Antonio Carotenuto, Simona Bonavita, Cinzia Valeria Russo, Giuseppe Fenu, Caterina Lapucci, Giorgia Teresa Maniscalco, Arianna Sartori, Francesca Caleri, Marco Capobianco, Alessio Signori, Rosa Iodice, Sara La Gioia, Giacomo Lus, Mauro Zaffaroni, Damiano Baroncini, Valeria Di Francescantonio, Russo, C. V., Sacca, F., Frau, J., Annovazzi, P., Signoriello, E., Bonavita, S., Grasso, R., Clerico, M., Cordioli, C., Laroni, A., Capobianco, M., Torri Clerici, V., Sartori, A., Cavalla, P., Maniscalco, G. T., La Gioia, S., Caleri, F., Giugno, A., Iodice, R., Carotenuto, A., Cocco, E., Fenu, G., Zaffaroni, M., Baroncini, D., Lus, G., Gallo, A., De Mercanti, S. F., Lapucci, C., Di Francescantonio, V., Brambilla, L., Sormani, M. P., Signori, A., Russo, CINZIA VALERIA, Sacca', Francesco, Frau, Jessica, Annovazzi, Pietro, Signoriello, Elisabetta, Bonavita, Simona, Grasso, Roberta, Clerico, Marinella, Cordioli, Cinzia, Laroni, Alice, Capobianco, Marco, Torri Clerici, Valentina, Sartori, Arianna, Cavalla, Paola, Teresa Maniscalco, Giorgia, La Gioia, Sara, Caleri, Francesca, Giugno, Alessia, Iodice, Rosa, Carotenuto, Antonio, Cocco, Eleonora, Fenu, Giuseppe, Zaffaroni, Mauro, Baroncini, Damiano, Lus, Giacomo, Gallo, Antonio, Federica De Mercanti, Stefania, Lapucci, Caterina, Di Francescantonio, Valeria, Brambilla, Laura, Pia Sormani, Maria, and Signori, Alessio

Subjects
Adult, safety, medicine.medical_specialty, efficacy, Multiple Sclerosis, Relapsing-Remitting, Natalizumab, Internal medicine, alemtuzumab, medicine, Humans, Glatiramer acetate, real-world evidence, Retrospective Studies, Expanded Disability Status Scale, Fingolimod Hydrochloride, business.industry, Multiple sclerosis, Glatiramer Acetate, cohort, medicine.disease, Fingolimod, Neurology, Relative risk, Cohort, Alemtuzumab, Neurology (clinical), business, medicine.drug
Abstract

Background and purpose: Real-world data on alemtuzumab are limited and do not provide evidence of its effectiveness after various disease-modifying therapies (DMTs). Our aim was to provide real-world data on the impact of clinical variables and previous DMTs on clinical response to alemtuzumab. Methods: Sixteen Italian multiple sclerosis centers retrospectively included patients who started alemtuzumab from January 2015 to December 2018, and recorded demographics, previous therapies, washout duration, relapses, Expanded Disability Status Scale (EDSS) score, and magnetic resonance imaging data. Negative binomial regression models were used to assess the effect of factors on annualized relapse (ARR) after alemtuzumab initiation. Results: We studied 322 patients (mean age 36.8years, median EDSS score 3, median follow-up 1.94years). Previous treatments were: fingolimod (106), natalizumab (80), first-line oral agents (56), first-line injectables (interferon/glatiramer acetate; 30), and other drugs (15). Thirty-five patients were treatment-naïve. The pre-alemtuzumab ARR was 0.99 and decreased to 0.13 during alemtuzumab treatment (p&nbsp

Published
2021

33. Cladribine vs other drugs in MS: Merging randomized trial with real-life data

Author

Domenico Ippolito, Sara La Gioia, Sabrina Esposito, Valentina Torri Clerici, Giorgia Teresa Maniscalco, Cinzia Cordioli, Lorena Pareja-Gutierrez, Elisabetta Signoriello, Cinzia Valeria Russo, Roberta Grasso, Doriana Landi, B. Frigeni, Andrea Visconti, Caterina Barrilà, Valeria Barcella, Raffaella Cerqua, Alice Laroni, Simona Bonavita, Stefania Barone, P. Perini, Sarah Rasia, Arianna Sartori, Maria Laura Stromillo, Roberta Lanzillo, Damiano Baroncini, Jessica Frau, Francesco Saccà, Luigi Lavorgna, Alessio Signori, Ignazio Roberto Zarbo, Giorgia Mataluni, Eleonora Cocco, Maria Pia Sormani, E Binello, Pietro Annovazzi, M Clerico, Simona Pontecorvo, Giuseppe Fenu, Alessia Di Sapio, Anna Maria Repice, Signori, A., Sacca, F., Lanzillo, R., Maniscalco, G. T., Signoriello, E., Repice, A. M., Annovazzi, P., Baroncini, D., Clerico, M., Binello, E., Cerqua, R., Mataluni, G., Perini, P., Bonavita, S., Lavorgna, L., Zarbo, I. R., Laroni, A., Pareja-Gutierrez, L., La Gioia, S., Frigeni, B., Barcella, V., Frau, J., Cocco, E., Fenu, G., Clerici, V. T., Sartori, A., Rasia, S., Cordioli, C., Stromillo, M. L., Di Sapio, A., Pontecorvo, S., Grasso, R., Barone, S., Barrila, C., Russo, C. V., Esposito, S., Ippolito, D., Landi, D., Visconti, A., Sormani, M. P., Signori, Alessio, Saccà, Francesco, Lanzillo, Roberta, Maniscalco, Giorgia Teresa, Signoriello, Elisabetta, Repice, Anna Maria, Annovazzi, Pietro, Baroncini, Damiano, Clerico, Marinella, Binello, Eleonora, Cerqua, Raffaella, Mataluni, Giorgia, Perini, Paola, Bonavita, Simona, Lavorgna, Luigi, Zarbo, Ignazio Roberto, Laroni, Alice, Pareja-Gutierrez, Lorena, La Gioia, Sara, Frigeni, Barbara, Barcella, Valeria, Frau, Jessica, Cocco, Eleonora, Fenu, Giuseppe, Clerici, Valentina Torri, Sartori, Arianna, Rasia, Sarah, Cordioli, Cinzia, Stromillo, Maria Laura, Di Sapio, Alessia, Pontecorvo, Simona, Grasso, Roberta, Barone, Stefania, Barrilà, Caterina, Russo, Cinzia Valeria, Esposito, Sabrina, Ippolito, Domenico, Landi, Doriana, Visconti, Andrea, and Sormani, Maria Pia

Subjects
Adult, Male, medicine.medical_specialty, Databases, Factual, Datasets as Topic, Settore MED/26, Placebo, Severity of Illness Index, law.invention, Multiple Sclerosis, Relapsing-Remitting, Natalizumab, Randomized controlled trial, law, Internal medicine, Outcome Assessment, Health Care, Severity of illness, medicine, Humans, Immunologic Factors, Multicenter Studies as Topic, Glatiramer acetate, Cladribine, Randomized Controlled Trials as Topic, Retrospective Studies, business.industry, Middle Aged, Fingolimod, Observational Studies as Topic, Neurology, Propensity score matching, Disease Progression, Female, Neurology (clinical), business, medicine.drug
Abstract

ObjectiveCladribine tablets were tested against placebo in randomized controlled trials (RCTs). In this study, the effectiveness of cladribine vs other approved drugs in patients with relapsing-remitting MS (RRMS) was compared by matching RCT to observational data.MethodsData from the pivotal trial assessing cladribine tablets vs placebo (CLARITY) were propensity score matched to data from the Italian multicenter database i-MuST. This database included 3,150 patients diagnosed between 2010 and 2018 at 24 Italian MS centers who started a disease-modifying drug. The annualized relapse rate (ARR) over 2 years from treatment start and the 24-week confirmed disability progression were compared between patients treated with cladribine and other approved drugs (interferon, glatiramer acetate, fingolimod, natalizumab, and dimethyl fumarate), with comparisons with placebo as a reference. Treatment effects were estimated by the inverse probability weighting negative binomial regression model for ARR and Cox model for disability progression. The treatment effect has also been evaluated according to baseline disease activity.ResultsAll weighted baseline characteristics were well balanced between groups. All drugs tested had an effect vs placebo close to that detected in the RCT. Patients treated with cladribine had a significantly lower ARR compared with interferon (relapse ratio [RR] = 0.48; p < 0.001), glatiramer acetate (RR = 0.49; p < 0.001), and dimethyl fumarate (RR = 0.6; p = 0.001); a similar ARR to that with fingolimod (RR = 0.74; p = 0.24); and a significantly higher ARR than natalizumab (RR = 2.13; p = 0.014), confirming results obtained by indirect treatment comparisons from RCTs (network meta-analyses). The relative effect of cladribine tablets 10 mg (cumulative dose 3.5 mg/kg over 2 years) was higher in patients with high disease activity vs all treatments except fingolimod and natalizumab. Effects on disability progression were largely nonsignificant, probably due to lack of power for such analysis.ConclusionIn patients with RRMS, cladribine tablets showed lower ARR compared with matched patients who started interferon, glatiramer acetate, or dimethyl fumarate; was similar to fingolimod; and was higher than natalizumab. The beneficial effect of cladribine tablets was generally amplified in the subgroup of patients with high disease activity.Classification of evidenceThis study provides Class III evidence that for patients with RRMS, cladribine-treated patients had lower ARR compared with interferon, glatiramer acetate, or dimethyl fumarate; similar ARR compared with fingolimod; and higher ARR compared with natalizumab.

Published
2020

34. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study

Author

Caterina Barrilà, Alice Laroni, Raffaella Cerqua, Giorgia Teresa Maniscalco, Alessia Di Sapio, Jessica Frau, Alessio Signori, A. Repice, Domenico Ippolito, Sara La Gioia, Giuseppe Fenu, Ignazio Roberto Zarbo, Francesco Saccà, Giorgia Mataluni, Sabrina Esposito, Elisabetta Signoriello, Arianna Sartori, Simona Bonavita, Eleonora Cocco, Roberta Lanzillo, Salvatore Lo Fermo, B. Frigeni, Valeria Barcella, Maria Pia Sormani, Simona Pontecorvo, E Binello, Pietro Annovazzi, Sarah Rasia, Cinzia Cordioli, Roberta Grasso, Valentina Torri Clerici, Damiano Baroncini, Lorena Pareja Gutierrez, Luigi Lavorgna, Marinella Clerico, Cinzia Valeria Russo, Fabio Gallo, Francesca Bovis, Silvia Rossi, Saccà, Francesco, Lanzillo, Roberta, Signori, Alessio, Maniscalco, Giorgia T, Signoriello, Elisabetta, Lo Fermo, Salvatore, Repice, Annamaria, Annovazzi, Pietro, Baroncini, Damiano, Clerico, Marinella, Binello, Eleonora, Cerqua, Raffaella, Mataluni, Giorgia, Bonavita, Simona, Lavorgna, Luigi, Zarbo, Ignazio Roberto, Laroni, Alice, Rossi, Silvia, Pareja Gutierrez, Lorena, La Gioia, Sara, Frigeni, Barbara, Barcella, Valeria, Frau, Jessica, Cocco, Eleonora, Fenu, Giuseppe, Torri Clerici, Valentina, Sartori, Arianna, Rasia, Sarah, Cordioli, Cinzia, Di Sapio, Alessia, Pontecorvo, Simona, Grasso, Roberta, Barrilà, Caterina, Russo, Cinzia Valeria, Esposito, Sabrina, Ippolito, Domenico, Bovis, Francesca, Gallo, Fabio, and Sormani, Maria Pia

Subjects
Persistence (psychology), Adult, Male, medicine.medical_specialty, Pediatrics, Neurology, Adolescent, naïve, relapsing–remitting, Therapy naive, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Multiple Sclerosis, Relapsing-Remitting, disease modifying therapies, Medicine, Humans, Immunologic Factors, 030212 general & internal medicine, real-life, Aged, Retrospective Studies, business.industry, Drug Substitution, Multiple sclerosis, Switch, persistence, Middle Aged, medicine.disease, Relapsing remitting, Italy, disease modifying therapies, naïve, persistence, real-life, relapsing–remitting, Switch, Neurology, Neurology (clinical), disease modifying therapie, Female, Neurology (clinical), business, Life study, 030217 neurology & neurosurgery
Abstract

Background: With many options now available, first therapy choice is challenging in multiple sclerosis (MS) and depends mainly on neurologist and patient preferences. Objectives: To identify prognostic factors for early switch after first therapy choice. Methods: Newly diagnosed relapsing–remitting MS patients from 24 Italian centers were included. We evaluated the association of baseline demographics, clinical, and magnetic resonance imaging (MRI) data to the switch probability for lack of efficacy or intolerance/safety with a multivariate Cox analysis and estimated switch rates by competing risks models. Results: We enrolled 3025 patients. The overall switch frequency was 48% after 3 years. Switch risk for lack of efficacy was lower with fingolimod (hazard ratio (HR) = 0.50; p = 0.009), natalizumab (HR = 0.13; p Conclusion: Several factors are associated with higher switch risk in patients starting a first-line therapy and could be integrated in the decision-making process of first treatment choice.

Published
2019

35. Italian Alemtuzumab Study Group. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

Author

Luca Prosperini, Pietro Annovazzi, Laura Boffa, Maria Chiara Buscarinu, Antonio Gallo, Manuela Matta, Lucia Moiola, Luigina Musu, Paola Perini, Carlo Avolio, Valeria Barcella, Assunta Bianco, Deborah Farina, Elisabetta Ferraro, Simona Pontecorvo, Franco Granella, Luigi M E Grimaldi, Alice Laroni, Giacomo Lus, Francesco Patti, Eugenio Pucci, Matteo Pasca, Paola Sarchielli, Angelo Ghezzi, Mauro Zaffaroni, Damiano Baroncini, Fabio Buttari, Diego Centonze, Arianna Fornasiero, Marco Salvetti, Renato Docimo, Elisabetta Signoriello, Gioacchino Tedeschi, Antonio Bertolotto, Marco Capobianco, Giancarlo Comi, Eleonora Cocco, Paolo Gallo, Marco Puthenparampil, Roberta Grasso, Valeria Di Francescantonio, Maria Rosaria Rottoli, Massimiliano Mirabella, Alessandra Lugaresi, Giovanna De Luca, Maria Di Ioia, Valeria Di Tommaso, Luca Mancinelli, Giancarlo Di Battista, Ada Francia, Serena Ruggieri, Carlo Pozzilli, Erica Curti, Elena Tsantes, Barbara Palmeri, Caterina Lapicci, Giovanni Luigi Mancardi, Antonio Uccelli, Clara Chisari, Emanuele D'Amico, Elisabetta Cartechini, Anna Maria Repice, Eliana Magnani, Luca Massaccesi, Paolo Calabresi, Massimiliano Di Filippo, Maria Di Gregorio, Prosperini, Luca, Annovazzi, Pietro, Boffa, Laura, Chiara Buscarinu, Maria, Gallo, Antonio, Matta, Manuela, Moiola, Lucia, Musu, Luigina, Perini, Paola, Avolio, Carlo, Barcella, Valeria, Bianco, Assunta, Farina, Deborah, Ferraro, Elisabetta, Pontecorvo, Simona, Granella, Franco, E Grimaldi, Luigi M, Laroni, Alice, Lus, Giacomo, Patti, Francesco, Pucci, Eugenio, Pasca, Matteo, Sarchielli, Paola, Ghezzi, Angelo, Zaffaroni, Mauro, Baroncini, Damiano, Buttari, Fabio, Centonze, Diego, Fornasiero, Arianna, Salvetti, Marco, Docimo, Renato, Signoriello, Elisabetta, Tedeschi, Gioacchino, Bertolotto, Antonio, Capobianco, Marco, Comi, Giancarlo, Cocco, Eleonora, Gallo, Paolo, Puthenparampil, Marco, Grasso, Roberta, Di Francescantonio, Valeria, Rosaria Rottoli, Maria, Mirabella, Massimiliano, Lugaresi, Alessandra, De Luca, Giovanna, Di Ioia, Maria, Di Tommaso, Valeria, Mancinelli, Luca, Di Battista, Giancarlo, Francia, Ada, Ruggieri, Serena, Pozzilli, Carlo, Curti, Erica, Tsantes, Elena, Palmeri, Barbara, Lapicci, Caterina, Luigi Mancardi, Giovanni, Uccelli, Antonio, Chisari, Clara, D'Amico, Emanuele, Cartechini, Elisabetta, Maria Repice, Anna, Magnani, Eliana, Massaccesi, Luca, Calabresi, Paolo, Di Filippo, Massimiliano, and Di Gregorio, Maria

Published
2018

36. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.

Author

Saccà F, Lanzillo R, Signori A, Maniscalco GT, Signoriello E, Lo Fermo S, Repice A, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Rossi S, Pareja Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Torri Clerici V, Sartori A, Rasia S, Cordioli C, Di Sapio A, Pontecorvo S, Grasso R, Barrilà C, Russo CV, Esposito S, Ippolito D, Bovis F, Gallo F, and Sormani MP

Subjects
Adolescent, Adult, Aged, Drug Substitution, Female, Humans, Italy, Male, Middle Aged, Retrospective Studies, Young Adult, Immunologic Factors adverse effects, Immunologic Factors therapeutic use, Multiple Sclerosis, Relapsing-Remitting drug therapy
Abstract

Background: With many options now available, first therapy choice is challenging in multiple sclerosis (MS) and depends mainly on neurologist and patient preferences., Objectives: To identify prognostic factors for early switch after first therapy choice., Methods: Newly diagnosed relapsing-remitting MS patients from 24 Italian centers were included. We evaluated the association of baseline demographics, clinical, and magnetic resonance imaging (MRI) data to the switch probability for lack of efficacy or intolerance/safety with a multivariate Cox analysis and estimated switch rates by competing risks models., Results: We enrolled 3025 patients. The overall switch frequency was 48% after 3 years. Switch risk for lack of efficacy was lower with fingolimod (hazard ratio (HR) = 0.50; p  = 0.009), natalizumab (HR = 0.13; p  < 0.001), dimethyl-fumarate (HR = 0.60; p  = 0.037), teriflunomide (HR = 0.21; p  = 0.031) as compared to interferons. Younger age (HR = 0.96; p  < 0.001), diagnosis delay (HR = 1.23; p  = 0.021), higher baseline Expanded Disability Status Scale (HR = 1.17; p  = 0.001), and spinal cord lesions (HR = 1.46; p  = 0.001) were independently associated with higher inefficacy switch rates. We found lower switch for intolerance/safety with glatiramer acetate (HR = 0.61; p  = 0.001), fingolimod (HR = 0.35; p  = 0.002), and dimethyl-fumarate (HR = 0.57; p  = 0.022) as compared to interferons, while it increased with natalizumab (HR = 1.43; p  = 0.022). Comorbidities were associated with intolerance switch (HR = 1.28; p  = 0.047)., Conclusion: Several factors are associated with higher switch risk in patients starting a first-line therapy and could be integrated in the decision-making process of first treatment choice.

Published
2019
Full Text
View/download PDF

37. Thromboembolism prophylaxis in laparoscopic surgery for gynecologic benign diseases. Results of a single center experience in 922 procedures.

Author

Sturlese E, Triolo O, Grasso R, Laganà AS, Retto A, Rossetti D, Vitale SG, Sarpietro G, and De Dominici R

Subjects
Adult, Elective Surgical Procedures, Emergencies, Female, Humans, Length of Stay statistics & numerical data, Retrospective Studies, Risk Assessment, Risk Factors, Smoking epidemiology, Thrombophilia etiology, Thrombophilia therapy, Young Adult, Early Ambulation, Genital Diseases, Female surgery, Laparoscopy, Venous Thromboembolism prevention & control
Abstract

Aim: The aim of this study is to assess the role of preoperative evaluation risk for venous tromboembolism (VTE) in patients submitted to laparoscopic surgery for gynecologic benign diseases., Methods: Date from nine hundred twenty-two women affected by adnexal benign diseases treated with laparoscopic procedures were collected and included in this study. VTE risk was assessed by "on line Caprini score calculator". Patients with one or more negative risk factors for Caprini's score underwent to venous thromboembolism prophylaxis (VTP). The remainign of the patients did not recived any VTP. A survey was conducted after three months from the discharge in order to collect the follow up date., Results: In our study 160 patients had a Caprini's score major than 2 and they have been subjected to VTP. A total of 762 patients were considered at low risk for VTE and they did not receive any VTP. In these patients was not registered any event of VTE., Discussion: The results of this study suggest that laparoscopic approach, when carried out in non-oncological patients and without any previous thromboembolic risk factor, is associated with a very low risk of VTE. This study also confirm what was reported by Ageno et al. 6, Nick et al. 7 and ACCP guidelines in 2012 8 in which routine thromboprophylaxis is recommended for patients with additional risk factors., Conclusions: Laparoscopic surgery in women for gynecologic benign diseases is associated with a very low risk of thromboembolism and therefore it does not require any mechanical or pharmacological thromboprophylaxis in the absence of risk factors. The systematic evaluation of VTE risk with the help of a standard calculator is highly recommended., Key Words: Gynaecology, Laparoscopic surgery, Thromboprophylaxis.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results